FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
Novartis
Pfizer
Pfizer
Enliven Therapeutics
Toray Industries, Inc
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Eli Lilly and Company
National University Hospital, Singapore
AbbVie
Canadian Cancer Trials Group
Gilead Sciences
Rutgers, The State University of New Jersey